<code id='C8FF440AA6'></code><style id='C8FF440AA6'></style>
    • <acronym id='C8FF440AA6'></acronym>
      <center id='C8FF440AA6'><center id='C8FF440AA6'><tfoot id='C8FF440AA6'></tfoot></center><abbr id='C8FF440AA6'><dir id='C8FF440AA6'><tfoot id='C8FF440AA6'></tfoot><noframes id='C8FF440AA6'>

    • <optgroup id='C8FF440AA6'><strike id='C8FF440AA6'><sup id='C8FF440AA6'></sup></strike><code id='C8FF440AA6'></code></optgroup>
        1. <b id='C8FF440AA6'><label id='C8FF440AA6'><select id='C8FF440AA6'><dt id='C8FF440AA6'><span id='C8FF440AA6'></span></dt></select></label></b><u id='C8FF440AA6'></u>
          <i id='C8FF440AA6'><strike id='C8FF440AA6'><tt id='C8FF440AA6'><pre id='C8FF440AA6'></pre></tt></strike></i>

          
          WSS
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge